XML 29 R16.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingencies (Tables)
3 Months Ended
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
Schedule of share purchase warrants outstanding
             
               
Number   Exercise Price   Expiry Date
150,000     $ 3.17     May 6, 2024
10,000     $ 12.00     April 21, 2026
160,000              
Schedule of outstanding stock purchase options
            
      Weighted  Weighted   
      Average  Average  Aggregate
   Number of  Exercise  Grant Date  intrinsic value
   Shares  Price ($)  Fair Value ($)  ($)
Outstanding, September 30, 2021    11,330,903    5.74         140,132,451 
Granted    2,358,000    10.13    7.07      
Forfeited    (118,750)   6.86    5.23      
Exercised    (400,537)   2.52    1.88    4,201,015 
Outstanding, September 30, 2022    13,169,616    6.61         62,267,309 
Granted    325,000    12.43    8.17      
Forfeited    (40,000)   7.51    2.52      
Exercised    (89,320)   2.89    2.44    591,993 
Outstanding, December 31, 2022    13,365,296    6.78         50,676,617 
Exercisable, December 31, 2022    8,795,293    4.51         45,930,627 
Schedule Of Share-based Payment Arrangement, Option, Activity
                 Weighted
         Weighted        average
         average        exercise
      Number of  remaining  Weighted     price
Range of exercise prices  outstanding  contractual  average  Number of  options
From  To  options  life (in years)  exercise price  vested options  vested
$0.92    2.96    3,850,742    4.86    2.29    3,844,908    2.29 
$3.15    4.80    2,042,500    5.09    3.30    2,032,500    3.29 
$5.04    8.98    3,927,054    5.80    6.29    2,374,554    6.31 
$9.20    13.01    1,968,000    9.04    10.73    154,581    12.27 
$13.22    24.58    1,577,000    8.24    18.51    388,750    18.80 
           13,365,296              8,795,293      
Schedule of general and administrative expenses and research and development expenses
          
   2022  2021
General and administrative  $1,742,524   $1,671,725 
Research and development   3,603,984    2,237,046 
Total stock-based compensation  $5,346,508   $3,908,771 
Schedule of weighted average assumptions for fair value of each option award
          
   2022  2021
Risk-free interest rate   4.07%   1.37%
Expected life of options (years)   4.98    6.50 
Annualized volatility   84.01%   96.79%
Dividend rate   0.00%   0.00%